Scholarlink

<p>Patients in the intensive care unit (ICU) with unhealthy alcohol use often experience agitation during mechanical ventilation, which can contribute to post-traumatic stress disorder (PTSD). The BACLOREA trial investigated whether high-dose baclofen could reduce agitation in these patients, but its long-term effects on PTSD symptoms remained unclear. This study aimed to assess whether baclofen administered during ICU stay to reduce the incidence of agitation could reduce the 5-year PTSD symptoms in adult patients with unhealthy alcohol use and improve long-term quality of life and psychological status. This observational follow-up study was conducted between September 2021 and February 2024 and included patients alive five years after participation in the BACLOREA trial, a randomized, placebo-controlled trial evaluating high-dose baclofen for the prevention of agitation-related events during mechanical ventilation in critically ill patients with unhealthy alcohol use. The primary outcome was the prevalence of PTSD symptoms measured using the Impact of Event Scale-Revised (IES-R), with a score ≥ 33 indicating PTSD symptoms. Secondary outcomes included the prevalence of PTSD symptoms using the PTSD Checklist Scale (PCL-S), the quality of life assessed through the SF-36, EQ-5D, and HADS scales. Among the 152 patients who survived five years after ICU admission, 94 (61.8%) completed the follow-up and were included in the BACLO-PTSD study. In this cohort, the 5-year prevalence of PTSD symptoms was 14.9%. For the primary outcome assessed with the IES-R, PTSD symptom prevalence was similar in the baclofen and placebo groups (13.0% vs. 16.7%, p = 0.62). Mean IES-R scores were 10.4 ± 12.5 in the baclofen group and 12.2 ± 13.5 in the placebo group (p = 0.49), while mean PCL-S scores were 25.4 ± 8.6 and 25.5 ± 7.0, respectively (p = 0.94). Quality of life and psychological status, assessed using the SF-36, EQ-5D, and HADS, were also comparable between groups. High-dose baclofen administered during mechanical ventilation did not reduce the 5-year prevalence of PTSD symptoms, nor did it impact quality of life or symptoms of anxiety and depression. Further research is needed to explore alternative strategies for preventing long-term psychological consequences in this population.</p><p><b>Trial registration&#xa0;:</b> NCT05877807, 03 april 2023, retrospectively registered.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of high-dose baclofen on post-traumatic stress disorder symptoms five years after hospitalization among critically ill patients with unhealthy alcohol use

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月8日

查看全文
  • Marwan Bouras,
  • Karim Asehnoune,
  • Yann Robert-Valli,
  • Pierre-Joachim Mahe,
  • Jean Reignier,
  • Adel Maamar,
  • Jean-Claude Lacherade,
  • Maud Jonas,
  • Boris Jung,
  • Martine Ferrandiere,
  • Samir Jaber,
  • Laurent Flet,
  • Mikael Moriconi,
  • Sigismond Lasocki,
  • Roland Smonig,
  • Christophe Guitton,
  • Stephan Ehrmann,
  • Bertrand Rozec,
  • Christelle Volteau,
  • Mickael Vourc’h,
  • Dominique Demeure Dit Latte,
  • Yannick Hourmant,
  • Noelle Brule,
  • Cédric Bretonniere,
  • Benjamin Gaborit,
  • Jean-Baptiste Lascarrou,
  • Laurent Nicolet,
  • Olivier Zambon,
  • Delphine Marest,
  • Jean-Marc Tadie,
  • Arnaud Gacouin,
  • Konstantinos Bachoumas,
  • Isabelle Vinatier,
  • Gwenhaël Colin,
  • Arthur Bailly,
  • Paul Morin,
  • Julien Lorber,
  • Vincent Brunot,
  • Kada Klouche,
  • Anne-Charlotte Tellier,
  • Benjamin Cohen,
  • Mathilde Barbaz,
  • Audrey De Jong,
  • Gerald Chanques,
  • Martine Tching-Sin,
  • Fabien Herve,
  • Guillaume Halley,
  • Soizic Gergaud,
  • Beatrice Lacombe,
  • Erwan L’Her,
  • Anne Renault,
  • Gwenael Prat,
  • Olivier Huet,
  • Hervé Floch,
  • Mickael Landais,
  • Emmanuel Mercier,
  • Olivier Mimoz,
  • Claire Dahyot,
  • Damien Du Cheyron

摘要

Patients in the intensive care unit (ICU) with unhealthy alcohol use often experience agitation during mechanical ventilation, which can contribute to post-traumatic stress disorder (PTSD). The BACLOREA trial investigated whether high-dose baclofen could reduce agitation in these patients, but its long-term effects on PTSD symptoms remained unclear. This study aimed to assess whether baclofen administered during ICU stay to reduce the incidence of agitation could reduce the 5-year PTSD symptoms in adult patients with unhealthy alcohol use and improve long-term quality of life and psychological status. This observational follow-up study was conducted between September 2021 and February 2024 and included patients alive five years after participation in the BACLOREA trial, a randomized, placebo-controlled trial evaluating high-dose baclofen for the prevention of agitation-related events during mechanical ventilation in critically ill patients with unhealthy alcohol use. The primary outcome was the prevalence of PTSD symptoms measured using the Impact of Event Scale-Revised (IES-R), with a score ≥ 33 indicating PTSD symptoms. Secondary outcomes included the prevalence of PTSD symptoms using the PTSD Checklist Scale (PCL-S), the quality of life assessed through the SF-36, EQ-5D, and HADS scales. Among the 152 patients who survived five years after ICU admission, 94 (61.8%) completed the follow-up and were included in the BACLO-PTSD study. In this cohort, the 5-year prevalence of PTSD symptoms was 14.9%. For the primary outcome assessed with the IES-R, PTSD symptom prevalence was similar in the baclofen and placebo groups (13.0% vs. 16.7%, p = 0.62). Mean IES-R scores were 10.4 ± 12.5 in the baclofen group and 12.2 ± 13.5 in the placebo group (p = 0.49), while mean PCL-S scores were 25.4 ± 8.6 and 25.5 ± 7.0, respectively (p = 0.94). Quality of life and psychological status, assessed using the SF-36, EQ-5D, and HADS, were also comparable between groups. High-dose baclofen administered during mechanical ventilation did not reduce the 5-year prevalence of PTSD symptoms, nor did it impact quality of life or symptoms of anxiety and depression. Further research is needed to explore alternative strategies for preventing long-term psychological consequences in this population.

Trial registration : NCT05877807, 03 april 2023, retrospectively registered.